Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.

Détails

Ressource 1Télécharger: BIB_A3F591D6E74E.P001.pdf (755.73 [Ko])
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_A3F591D6E74E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.
Périodique
Plos One
Auteur(s)
Hysek C.M., Simmler L.D., Nicola V.G., Vischer N., Donzelli M., Krähenbühl S., Grouzmann E., Huwyler J., Hoener M.C., Liechti M.E.
ISSN
1932-6203 (Electronic)
ISSN-L
1932-6203
Statut éditorial
Publié
Date de publication
2012
Volume
7
Numéro
5
Pages
e36476
Langue
anglais
Notes
Publication types: Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the effects of 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release of both 5-HT and NE by MDMA or by its metabolite 3,4-methylenedioxyamphetamine from transmitter-loaded human cells expressing the 5-HT or NE transporter. In humans, duloxetine inhibited the effects of MDMA including elevations in circulating NE, increases in blood pressure and heart rate, and the subjective drug effects. Duloxetine inhibited the pharmacodynamic response to MDMA despite an increase in duloxetine-associated elevations in plasma MDMA levels. The findings confirm the important role of MDMA-induced 5-HT and NE release in the psychotropic effects of MDMA. Duloxetine may be useful in the treatment of psychostimulant dependence. TRIAL REGISTRATION: Clinicaltrials.gov NCT00990067.
Mots-clé
3,4-Methylenedioxyamphetamine/antagonists & inhibitors, 3,4-Methylenedioxyamphetamine/pharmacology, Adult, Biological Transport/drug effects, Female, Humans, Laboratories, Male, N-Methyl-3,4-methylenedioxyamphetamine/antagonists & inhibitors, Norepinephrine/secretion, Placebo Effect, Receptors, Adrenergic/metabolism, Serotonin/secretion, Serotonin Plasma Membrane Transport Proteins/metabolism, Thiophenes/adverse effects, Thiophenes/metabolism
Pubmed
Web of science
Création de la notice
22/07/2012 22:20
Dernière modification de la notice
03/03/2018 20:12
Données d'usage